| |
Board of Directors
Mr. Levangie, Chairman of the Board, is also
the non-executive Chairman of the Board of Directors of eV3 Inc. (NASDAQ:EVVV).
Beginning in 1992 Mr. Levangie was a member of the senior management team of
Cytyc Corporation, a leading provider of surgical and diagnostic products
targeting women's health and cancer diagnostics. Most recently he served as
President of Cytyc's Surgical Products Division, Executive Vice President
and a director of Cytyc Corporation. Following Cytyc Corporation's merger
with Hologic, Inc. in October of 2007, Mr. Levangie has remained as a director
of Hologic, Inc. Prior to Cytec, Mr. Levangie held a variety of sales and
marketing positions at Abbott Laboratories. In addition to his other commitments,
Mr. Levangie also serves as Director of Dune Medical Devices, Ltd., a privately-held
medical device company engaged in the development and commercialization of devices
for real-time tissue characterization. Mr. Levangie received a B.S. in Pharmacy
from Northeastern University.
Mr. Carbeau, President and Chief Executive Officer,
brings to HyperMed 25 years experience in building healthcare and medical technology
companies. Most recently Mark was US President of Kinetics Concepts, Inc. (NYSE: KCI)
where he led the Advanced Wound Care business. In other operating roles, he was Vice
President Corporate Development of OraPharma, Inc. during its IPO in March of 2000
and prior to its sale to Johnson and Johnson in 2002, and held roles with Eli Lilly
and Company in sales, marketing and engineering. Mark has been an engagement manager
with The Boston Consulting Group, and a founding partner of a boutique consulting
firm providing transaction support and interim management to private equity clients.
He holds a BS degree in Industrial Engineering from Penn State University and an MBA
from The Wharton School.
Mr. Lifsitz, Chief Operating Officer,
is a serial entrepreneur, having been a co-founder of e-Travel
(sold to Oracle), DataPower Technology (sold to IBM) and a senior
executive at AMICAS (sold via reverse public merger - NASDAQ:
AMCS). He brings over two decades of senior operating, sales/business
development, software development and company building experience
to HYPERMED. Rick has been a consultant with The Boston Consulting
Group (BCG), a partner at a management turnaround firm and has
marketing and business development experience at Procter and Gamble
and Digital Equipment Corporation. Rick graduated summa cum laude
from the University of Michigan & holds a MBA degree from
The Harvard Business School.
Dr. Denner serves as a Managing Director of
entities affiliated with Carl Icahn, including Icahn Partners
LP and Icahn Partners Master Fund LP. Icahn Partners LP and Icahn
Partners Master Fund LP are private investment funds. From April
2005 to May 2006, Dr. Denner served as a portfolio manager specializing
in healthcare investments for Viking Global Investors and, previously,
served as a health care portfolio manager with Morgan Stanley
Investment Management. Dr. Denner currently serves as a director
of Imclone Systems, Inc. Dr. Denner received his S.B. from the
Massachusetts Institute of Technology and, an M.S., M.Phil. and
Ph.D. from Yale University.
Dr. Goldblatt is currently the CEO of Functional
Genetics in Washington, DC. From 1999 to 2003, he served as Director
of Defense Sciences at the Defense Advanced Research Projects
Agency (DARPA) where he laid the foundation to make biological
research an integral part of the Department of Defense. This includes
programs to defend against biological threats and leverage biology
to enhance both defense systems and human performance. Prior to
his work with the Department of Defense, Dr. Goldblatt spent 12
years with McDonald's Corporation as the Science and Technology
Officer where he had broad responsibilities in the areas of nutrition,
product development, food safety, and corporate venture capital.
In his capacity with General Foods, he led research efforts in
the use of nutrients for pharmaceutical effects and oversaw a
variety of regulatory and legal issues. Dr. Goldblatt received
his B.A. from Reed College and his Ph.D. and J.D. from the University
of California, Davis.
Dr. Lind has over 20 years of experience in
a variety of life science related professions, ranging from physician
to head of biotech equity research at Morgan Stanley to head of
a life sciences hedge fund. Most recently, he was Managing Partner
of Accendx Management, LLC, a Greenwich, CT based hedge fund he
co-founded. Prior, he was senior biotechnology equity research
analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber
from 1995 to 1997. Previously, he was Managing Director of Lind
& Co., a Boston-based biotechnology investment research firm
serving institutional clients, which he founded in 1991. He is
a former Tufts University Clinical Fellow in Medicine and a past
member of the American Medical Association Council on Ethical
and Judicial Affairs. During his tenure on the Council, he worked
extensively on problems of resource allocation in health care.
He has served on numerous national health policy bodies, including
the Health Policy Agenda for the American People and the American
Medical Association Task Force on Physician Manpower.
Dr. Lind is a graduate of the University of Iowa College of Medicine,
1987. From 1990 to 1992, he was a practicing physician in Brookline,
Massachusetts. He served as an attending physician at St. Elizabeth's
Hospital in Boston, a major teaching affiliate of Tufts University
School of Medicine, where he completed his residency in Internal
Medicine.
|
|
|
